Stock HPIC HAYAT PHARMACEUTICAL INDUSTRIES CO. PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hayat Pharmaceutical Industries Co. PLC

Equities

HPIC

JO4121011012

Pharmaceuticals

End-of-day quote Amman S.E.
Other stock markets
 18:00:00 2024-05-08 EDT 		5-day change 1st Jan Change
2.47 JOD 0.00% Intraday chart for Hayat Pharmaceutical Industries Co. PLC -2.37% +2.92%
04-29 Hayat Pharmaceutical Industries Co. PLC Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-31 Hayat Pharmaceutical Industries Co. PLC Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 18.34 18.62 22.99 36 28.02 22.8
Enterprise Value (EV) 1 16.45 16.93 19.3 30.36 22.59 17.49
P/E ratio 5.83 x 5.59 x 6.55 x 9.89 x 7.94 x 9.8 x
Yield - 5.1% 8.26% 6.6% 8.47% 6.88%
Capitalization / Revenue 1.3 x 1.19 x 1.39 x 2.17 x 1.64 x 1.44 x
EV / Revenue 1.16 x 1.08 x 1.16 x 1.83 x 1.32 x 1.11 x
EV / EBITDA 4.28 x 3.7 x 4.14 x 5.71 x 4.3 x 4.45 x
EV / FCF -14.1 x 70.8 x 9.74 x 10.4 x 21.8 x 10.7 x
FCF Yield -7.12% 1.41% 10.3% 9.63% 4.58% 9.36%
Price to Book 0.84 x 0.78 x 0.9 x 1.28 x 0.95 x 0.78 x
Nbr of stocks (in thousands) 9,500 9,500 9,500 9,500 9,500 9,500
Reference price 2 1.930 1.960 2.420 3.790 2.950 2.400
Announcement Date 19-03-28 20-05-19 22-03-24 22-03-24 23-02-12 24-03-31
1JOD in Million2JOD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 14.12 15.64 16.58 16.58 17.11 15.81
EBITDA 1 3.843 4.575 4.666 5.321 5.258 3.927
EBIT 1 3.501 4.11 4.187 4.422 4.204 2.839
Operating Margin 24.79% 26.28% 25.25% 26.67% 24.58% 17.96%
Earnings before Tax (EBT) 1 3.379 3.75 4.08 4.331 4.136 2.741
Net income 1 3.144 3.332 3.511 3.642 3.529 2.328
Net margin 22.26% 21.3% 21.17% 21.96% 20.63% 14.73%
EPS 2 0.3309 0.3507 0.3695 0.3834 0.3714 0.2450
Free Cash Flow 1 -1.17 0.2389 1.982 2.924 1.035 1.636
FCF margin -8.29% 1.53% 11.95% 17.63% 6.05% 10.35%
FCF Conversion (EBITDA) - 5.22% 42.48% 54.94% 19.69% 41.67%
FCF Conversion (Net income) - 7.17% 56.46% 80.27% 29.34% 70.29%
Dividend per Share - 0.1000 0.2000 0.2500 0.2500 0.1650
Announcement Date 19-03-28 20-05-19 22-03-24 22-03-24 23-02-12 24-03-31
1JOD in Million2JOD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1.89 1.69 3.69 5.65 5.44 5.31
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.17 0.24 1.98 2.92 1.04 1.64
ROE (net income / shareholders' equity) 15.1% 14.6% 13.9% 13.3% 12.3% 7.93%
ROA (Net income/ Total Assets) 8.4% 9.14% 8.63% 8.49% 7.84% 5.19%
Assets 1 37.42 36.46 40.7 42.91 45.02 44.87
Book Value Per Share 2 2.300 2.520 2.690 2.970 3.090 3.090
Cash Flow per Share 2 0.4700 0.3300 0.6000 0.7600 0.7000 0.7600
Capex 1 3.92 1.49 0.77 1.59 0.87 0.34
Capex / Sales 27.8% 9.51% 4.67% 9.56% 5.11% 2.14%
Announcement Date 19-03-28 20-05-19 22-03-24 22-03-24 23-02-12 24-03-31
1JOD in Million2JOD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
HAYAT PHARMACEUTICAL INDUSTRIES CO. PLC Stock Hayat Pharmaceutical Industries Co. PLC
+2.92% 33.11M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HPIC Stock
  4. Financials Hayat Pharmaceutical Industries Co. PLC
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW